NEW YORK (GenomeWeb) – OncoDNA said today that it signed a distribution agreement with Providens to market and distribute its cancer genomic tests to oncologists and their patients in Croatia, Bosnia-Herzegovina, Slovenia, Serbia, Montenegro, and Macedonia.
Providens will give physicians in the region access to OncoDNA's molecular profiling technology, which combines analysis of liquid and solid biopsies for patients with metastatic cancer, the company said.
OncoDNA offers a variety of molecular tests for guiding cancer treatment, including OncoDeep, a solid tumor test that uses NGS, FISH, immunohistochemistry, and other approaches; and OncoTrace, which is a blood-based sequencing test that targets mutations in a panel of 28 genes.
"This partnership is an important step towards granting patients across South East Europe access to our smart cancer precision medicine solutions," Fiona Demol, OncoDNA's international business development manager, said in a statement.